ALNY FY 2020 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$493M+124.3% YoY

Gross Profit

$415M84.2% margin

Operating Income

-$828M-168.1% margin

Net Income

-$858M-174.1% margin

EPS (Diluted)

$-7.46

Cash Flow

Operating Cash Flow

-$615M

Free Cash Flow

-$685M

Stock-Based Comp.

$140M

Balance Sheet

Total Assets

$3.4B

Total Liabilities

$2.4B

Stockholders' Equity

$1.0B

Cash & Equivalents

$497M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$493M	$220M	+124.3%
Gross Profit	$415M	$195M	+113.1%
Operating Income	-$828M	-$939M	+11.8%
Net Income	-$858M	-$886M	+3.1%